FAP-targeted [177Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer. (PubMed, Nucl Med Biol) - Oct 9, 2026 - "[177Lu]Lu-FAP-2286 acts as a potent immune sensitizer for STING agonist therapy. This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer."
Journal • Lung Cancer • Oncology • Solid Tumor • CD8 • FAP • IFNB1 • PTPRC
|
|
Dazhi Shi; Hubing Wu; Jiahao Xie; Lijuan Wang; Meng Wang; Pei Han; Wenlan Zhou; Yijin Zou; Ying Tian; Yuhao Huang
|